← Back to Treatments
🏅 FDA Orphan Designation

OCALIVA

obeticholic acid

Manufacturer: Intercept Pharmaceuticals, Inc.

Indicated for:
Primary biliary cholangitisOrphan

FDA-Approved Indications (1)

Primary biliary cholangitisOrphan Designation

Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA

Indications & Usage

Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA

💙 Support Programs

View all →
OCALIVA
Intercept Pharmaceuticals, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.